



PRESS RELEASE

Addition to Moberg Pharma's management team

STOCKHOLM, June 20th, 2018, Moberg Pharma AB (OMX: MOB) announced the appointment of Mark Beveridge as Vice President Finance and member of the management team, effective from July 1st 2018. Mark Beveridge has held various finance positions at Moberg Pharma since 2015 and was previously a senior advisor to the company.

Mark Beveridge has been appointed Vice President Finance and permanent member of the management team, effective from July 1st 2018. Mark joined Moberg Pharma as a Business Controller in 2015, previously having acted as senior advisor to the company on accounting and ERP issues. Since then, he has been a key member of Moberg's transaction and finance team. Mark brings extensive experience within system and financial management with a strong background in accounting, assurance and advisory services. Originally from Sydney, Australia, where Mark qualified as a Chartered Accountant, Mark has worked with a broad range of SMEs and publicly listed entities. He was previously a Senior Adviser at Visma Services and held advisory and executive roles in a number of high growth e-commerce platforms, including BuyInvite.com.au (now part of Mysale Group Plc).

"Over the past years, Mark Beveridge has played a key role in Moberg Pharma's finance and transaction teams. It's a pleasure to welcome Mark to the management team and I look forward to working together with him to continue developing Moberg Pharma's operations" says Peter Wolpert, CEO of Moberg Pharma.

For additional information, please contact:

Peter Wolpert, CEO, telephone: +1 908 432 22 03 (US), +46 70 735 71 35, e-mail: peter.wolpert@mobergpharma.se

Mark Beveridge, VP Finance, telephone: +46 76-805 82 88, e-mail: mark.beveridge@mobergpharma.se

About this information

The information was released for public distribution on June 20th 2018 at 11:00 am CET by the contact persons above.

About Moberg Pharma, www.mobergpharma.com

Moberg Pharma AB (publ.) is a rapidly growing Swedish pharmaceutical company with OTC sales operations in the U.S. and a distributor network in more than 30 countries. The company's portfolio includes the OTC brands Kerasal[®], Kerasal Nail[®], New Skin[®], Dermoplast[®] and Domeboro[®]. Kerasal Nail[®] (Emtrix[®], Zanmira[®] or Nalox[™] in certain markets) is a leading OTC treatment of nail disorders in the U.S., Canada as well as in several markets in EU and Southeast Asia. The company is growing organically as well as through acquisitions. Internal development programs focus on innovative drug delivery of proven compounds and include two assets in late-stage clinical development, MOB-015 (onychomycosis, phase 3 studies ongoing) and BUPI (pain management in oral mucositis, preparations for phase 3 studies ongoing). Moberg Pharma has offices in Stockholm and New Jersey and the company's shares are listed on the Small Cap list of the NASDAQ OMX Nordic Exchange Stockholm (OMX: MOB).